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N E W  S C I E N C E
Gene-therapy, the technique of inserting genes into cells to treat disease, holds promise 
for many areas of medicine. For Zhuo-Hua Pan, 
Ph.D., professor of anatomy and cell biology in the 
School of Medicine, and Sean Ainsworth, founder 
of RetroSense Therapeutics LLC, the breakthrough 
therapy means restoring vision to millions of people 
suffering with incurable blindness. 
Pan, along with colleagues at Salus University, 
has developed a novel gene-therapy approach for 
treating blindness caused by age-related macular 
degeneration (AMD) and retinitis pigmentosa (RP) – 
disorders that are currently incurable. The treatment 
delivers a photoreceptor gene from blue-green algae, 
which converts previously non-photosensitive 
retinal cells to photosensitive cells. The result is 
restored light responses in the retina. 
AMD is the leading cause of blindness in people 
over 60, affecting more than 8 million people in 
the U.S. alone. Worldwide, 500,000 individuals lose 
their eyesight annually due to AMD, which is the 
result of progressive deterioration of the macula, the 
central portion of the retina. 
RP is a genetically-determined eye disease 
caused by any of 100 different genes. An estimated 
100,000 people in the U.S. have RP, which typically 
manifests as night blindness and progresses to 
tunnel vision and sometimes complete blindness. 
Other technologies being developed to restore 
vision in patients with AMD and RP include 
implanted devices and stem cell technologies. 
However, stem cells can cause damage to 
surrounding cells and implanted devices are highly 
invasive and suffer from poor resolution.  Pan’s 
technology holds the potential to restore vision 
while avoiding these negative side effects. 
Ainsworth licensed the technology from Wayne 
State University in an effort to eventually test 
the technology in humans. While there is at least 
six years of research and testing needed before 
anything can be brought to the market, FDA Phase I 
tests should begin in early 2012.
With this technology, combined the business 
expertise of Ainsworth, a seasoned life sciences 
consultant and entrepreneur, Pan is hopeful his 
breakthrough treatment is on the fast track to 
restoring a vital part of the human experience for 
millions of people worldwide. 
To learn more about RetroSense, visit:
http://www.retro-sense.com/
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